On February 4, 2026, Evogene Ltd. announced an exclusive licensing agreement between its subsidiary Biomica Ltd. and Shanghai Lishan Biopharmaceuticals for the microbiome-based therapeutic BMC128, allowing Lishan Biotech to develop and commercialize the treatment. This agreement includes milestone payments and royalties for Biomica based on Lishan’s clinical trial progress and sales.